Stockscreener 앱 받기
14.00
5.82%
0.77
시간 외 거래:
14.00
전일 마감가:
$13.23
열려 있는:
$13.36
하루 거래량:
351.05K
Relative Volume:
1.14
시가총액:
$240.77M
수익:
-
순이익/손실:
$-52.60M
주가수익비율:
-10.48
EPS:
-1.3361
순현금흐름:
$-35.80M
1주 성능:
-10.05%
1개월 성능:
+13.09%
6개월 성능:
+105.58%
1년 성능:
+123.64%
1일 변동 폭
$13.30
$14.08
1주일 범위
$13.22
$15.89
52주 변동 폭
$4.63
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
명칭
Tenax Therapeutics Inc
전화
919-855-2100
주소
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
14.00 | 227.52M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 개시 | Piper Sandler | Overweight |
| 2024-10-24 | 개시 | Leerink Partners | Outperform |
| 2024-10-14 | 개시 | Guggenheim | Buy |
| 2024-09-30 | 개시 | William Blair | Outperform |
| 2017-05-18 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 개시 | MLV & Co | Buy |
| 2014-11-18 | 개시 | WallachBeth | Buy |
모두보기
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX) - Seeking Alpha
Tenax Therapeutics (TENX): Cantor Fitzgerald Initiates Coverage with Overweight Rating | TENX Stock News - GuruFocus
Top Cypherpunk Technologies (CYPH) Competitors 2026 - MarketBeat
Published on: 2026-03-17 23:42:59 - baoquankhu1.vn
Tenax stock wins bullish view at Cantor (TENX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - MarketBeat
Tenax Therapeutics (TENX) Gains Momentum with Phase 3 Trial - GuruFocus
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX - MarketBeat
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | - GuruFocus
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price - MarketBeat
What is Lifesci Capital’s Forecast for TENX Q1 Earnings? - Defense World
What is Lifesci Capital's Forecast for TENX Q1 Earnings? - MarketBeat
Trading Systems Reacting to (TENX) Volatility - Stock Traders Daily
Logos Global Management LP Acquires 615,000 Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Raised to "Strong-Buy" at Lifesci Capital - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026 - Meyka
Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates - AlphaStreet
Christopher Giordano Discloses Investment at Tenax Therapeutics with 6.79% Stake - TradingView
Tenax Therapeutics (TENX) CEO reports 6.79% beneficial ownership stake - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
TENX: LEVEL trial enrollment completed early; global expansion and regulatory preparations advancing - TradingView
Tenax Therapeutics stock gains as trial enrollment complete By Investing.com - Investing.com Canada
Tenax Therapeutics Achieves Phase 3 LEVEL Study Patient Target and Reports 2025 Financial Results; Topline Data Expected Q3 2026 - Minichart
Tenax Therapeutics stock holds at Outperform at Leerink Partners By Investing.com - Investing.com Canada
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tenax Therapeutics Reports Q4 Loss - National Today
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics, Inc. 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Challenges - Minichart
Tenax Therapeutics 2025 Financials: Q4 Loss Beats Analyst EstimatesNews and Statistics - IndexBox
TENAX Therapeutics 10-K: Net loss $52.6M, NOL $56.4M, cash runway into 2027 - TradingView
Tenax Therapeutics (NASDAQ: TENX) outlines Phase 3 PH-HFpEF strategy - Stock Titan
TENX: LEVEL and LEVEL-2 trials advanced, net loss widened, cash reserves support operations through 2027 - TradingView
Tenax Therapeutics (TENX) Completes Patient Enrollment for Phase 3 LEVEL Study - GuruFocus
Tenax Therapeutics (NASDAQ: TENX) ramps Phase 3 TNX-103 trials and widens 2025 loss - Stock Titan
Tenax Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Tenax Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
TENX Technical Analysis & ETF Price Forecast - Intellectia AI
Tenax Therapeutics Inc (TENX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):